Eli Lilly has established itself as a powerhouse in the pharmaceutical industry, with a particular focus on diabetes care, oncology, immunology, and neuroscience. The company's recent success has ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

but taking into account the huge need there would probably continue to be supply constraints until we had an oral medicine with an injectable-like efficacy,” President of Lilly Diabetes and ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose around a third over the prior year.

Pharma major Lupin has acquired Huminsulin brand in India from Eli Lilly, in an effort to enhance its diabetes portfolio, the company said in an exchange filing on December 30. Lupin had been ...

Shares of Eli Lilly & Co. were headed for their worst ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

Novo's Ozempic is approved by the U.S. Food and Drug Administration (FDA) to treat diabetes, while Wegovy is primarily prescribed for obesity care. In the same vein, Lilly's Mounjaro is approved ...

Photo Credit: vitapix Drugmaker Lupin Ltd has acquired Huminsulin in India from Eli Lilly and Company, for an undisclosed amount. The move will strengthen Lupin’s diabetes footprint in the country.

Global pharma major Lupin Limited on Monday announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. According to the company ...